|
?:authorAffiliation
|
-
[\'Institute for Global Health and Infectious Diseases, Division of Pulmonary Diseases and Critical Care Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.\', \'Department of Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.\', \'Ridgeback Biotherapeutics LP, Miami, FL, USA.\', \'Pharstat Inc., Raleigh, NC, USA.\', \'Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.\', \'Gillings School of Global Public Health, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.\', \'Department of Medicine, Division of Infectious Diseases, Duke University Medical Center, Durham, NC, USA.\', \'Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.\', \'Valley Clinical Trials Inc., Northridge, CA, USA.\', \'KBE Consulting, Raleigh, NC, USA.\', \'Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.\', \'Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}